Developer docs
API playgroundTry for free, no card

Search company profiles

Microbiome Therapeutics

Full company profile

uuid0005fvh

Namestring
Microbiome Therapeutics
Websiteurl
mbiome.com
Company typeenum
Private
Founded yearint
2009
Short descriptiontext

Microbiome Therapeutics is a private biotechnology company founded in 2009 and based in Broomfield, Colorado that develops medical food and pharmaceutical products in the human microbiome space, though it shows no active operational signals after 2017.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBroomfield, United States
HQ citystring
Broomfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical food products, microbiome therapeutics, pharmaceutical development, biotechnology research, human microbiome applications
Industry1 code
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Microbiome Therapeutics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Microbiome Therapeutics and Medical Foods
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MicroBiome Therapeutics is a biotechnology company that develops medical food and pharmaceutical products based on microbiome science. The company focuses on therapeutic and nutrition applications within the human microbiome domain.

Differentiator
Functional benefit
Problem solved
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Peers10 records
1Seres Therapeutics
TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined consortia of bacteria for serious diseases; directly comparable to Microbiome Therapeutics in therapeutic category and product modality.

2Vedanta Biosciences
TypeDirect peer
Description

Develops defined bacterial consortium products for immune-mediated diseases using microbiome-based approaches; closely aligned in therapeutic focus and platform modality.

3Finch Therapeutics Group
TypeDirect peer
Description

Microbiome therapeutics company developing oral encapsulated microbial consortia for recurrent C. difficile and other indications; directly comparable in delivery format and indication areas.

4Rebiotix (a Ferring company)
TypeDirect peer
Description

Pioneer in microbiome-based therapeutics with the FDA-approved RBX2660 (Rebyota) for recurrent C. difficile; a directly comparable microbiome therapeutics developer.

5Assembly Biosciences
TypeBroad incumbent
Description

Clinical-stage biotechnology company developing therapeutics for serious diseases, with historical work in microbiome-modulating programs; broader biotech incumbent with overlapping therapeutic ambitions.

64D pharma
TypeDirect peer
Description

Develops live biotherapeutic products (LBPs) using single-strain and defined-consortium approaches; closely comparable in product modality and regulatory pathway.

7MaaT Pharma
TypeRegional player
Description

European clinical-stage company developing microbiome-based therapies, including standardized fecal microbiota suspensions; comparable in modality though primarily serving European clinical sites.

8Evelo Biosciences
TypeEmerging player
Description

Developed microbiome-based oral medicines targeting immune-mediated diseases; comparable in therapeutic intent and oral-delivery format, though program has since been wound down.

9Second Genome
TypeEmerging player
Description

Microbiome-focused drug discovery company using microbial insights to identify therapeutic targets; comparable in microbiome R&D approach and therapeutic area breadth.

10Synlogic
TypeDirect peer
Description

Developed Synthetic Biotic medicines — engineered live microbial therapeutics — a directly comparable approach to microbial-based product development in the therapeutic space.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microbiome Therapeutics

Microbiome Therapeutics and Medical Foodsmbiome.com

Microbiome Therapeutics is a private biotechnology company founded in 2009 and based in Broomfield, Colorado that develops medical food and pharmaceutical products in the human microbiome space, though it shows no active operational signals after 2017.

Microbiome Therapeutics firmographics

Firmographics
Name
Microbiome Therapeutics
Website
https://mbiome.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Microbiome Therapeutics is a private biotechnology company founded in 2009 and based in Broomfield, Colorado that develops medical food and pharmaceutical products in the human microbiome space, though it shows no active operational signals after 2017.
Ownership category
akta.pro rank

Microbiome Therapeutics industry classification

Industry
Product category
Microbiome Therapeutics and Medical Foods
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Microbiome Therapeutics

Keywords

  • Medical food products
  • Microbiome therapeutics
  • Pharmaceutical development
  • Biotechnology research
  • Human microbiome applications

Where Microbiome Therapeutics is headquartered

Location

Headquarters

HQ city
Broomfield
HQ country
United States
HQ region
North America

Markets served

Microbiome Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Microbiome Therapeutics product offering

Product offering

Core offering

MicroBiome Therapeutics is a biotechnology company that develops medical food and pharmaceutical products based on microbiome science. The company focuses on therapeutic and nutrition applications within the human microbiome domain.

Differentiator

Problem solved

Functional benefit

Companies that use Microbiome Therapeutics

Customer profile

Ideal customer profiles1 record

Microbiome Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Microbiome Therapeutics partnerships and signals

Strategic signal

Scale indicators4 records

Microbiome Therapeutics competitors and assessment

Company assessment

Direct peers

  • Seres Therapeutics: Clinical-stage microbiome therapeutics company developing defined consortia of bacteria for serious diseases; directly comparable to Microbiome Therapeutics in therapeutic category and product modality.
  • Vedanta Biosciences: Develops defined bacterial consortium products for immune-mediated diseases using microbiome-based approaches; closely aligned in therapeutic focus and platform modality.
  • Finch Therapeutics Group: Microbiome therapeutics company developing oral encapsulated microbial consortia for recurrent C. difficile and other indications; directly comparable in delivery format and indication areas.
  • Rebiotix (a Ferring company): Pioneer in microbiome-based therapeutics with the FDA-approved RBX2660 (Rebyota) for recurrent C. difficile; a directly comparable microbiome therapeutics developer.
  • 4D pharma: Develops live biotherapeutic products (LBPs) using single-strain and defined-consortium approaches; closely comparable in product modality and regulatory pathway.
  • Synlogic: Developed Synthetic Biotic medicines — engineered live microbial therapeutics — a directly comparable approach to microbial-based product development in the therapeutic space.

Broad incumbents

  • Assembly Biosciences: Clinical-stage biotechnology company developing therapeutics for serious diseases, with historical work in microbiome-modulating programs; broader biotech incumbent with overlapping therapeutic ambitions.

Regional players

  • MaaT Pharma: European clinical-stage company developing microbiome-based therapies, including standardized fecal microbiota suspensions; comparable in modality though primarily serving European clinical sites.

Emerging players

  • Evelo Biosciences: Developed microbiome-based oral medicines targeting immune-mediated diseases; comparable in therapeutic intent and oral-delivery format, though program has since been wound down.
  • Second Genome: Microbiome-focused drug discovery company using microbial insights to identify therapeutic targets; comparable in microbiome R&D approach and therapeutic area breadth.

Market position

Customer concentration

Microbiome Therapeutics social profiles

Digital presence

Microbiome Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microbiome Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Microbiome Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microbiome Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbiome Therapeutics

What does Microbiome Therapeutics do?

MicroBiome Therapeutics is a biotechnology company that develops medical food and pharmaceutical products based on microbiome science. The company focuses on therapeutic and nutrition applications within the human microbiome domain.

Is Microbiome Therapeutics a public or private company?

Microbiome Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Microbiome Therapeutics founded?

Microbiome Therapeutics was founded in 2009. It employs 1 to 10 people.

Where is Microbiome Therapeutics based?

Microbiome Therapeutics is headquartered in Broomfield, United States, in the North America region.

Who are Microbiome Therapeutics's main competitors?

Direct peers on record are Seres Therapeutics, Vedanta Biosciences, Finch Therapeutics Group, Rebiotix (a Ferring company), 4D pharma and Synlogic. Assembly Biosciences is listed as a broad incumbent. MaaT Pharma is listed as a regional player. Emerging players are Evelo Biosciences and Second Genome.

Does Microbiome Therapeutics have an API?

No public API is recorded for Microbiome Therapeutics.

What industry is Microbiome Therapeutics in?

Microbiome Therapeutics's product category is Microbiome Therapeutics and Medical Foods. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FortunebusinessinsightsHuman Microbiome Market Size, Industry ShareThe global human microbiome market was valued at USD 1.22 billion in 2025 and is projected to reach USD 14.41 billion by 2034, growing at a compound annual growth rate of 31.61% during the forecast period. The market covers products and technologies that analyze, modify, and utilize microbial communities within the human body for health improvement across therapeutics, diagnostics, and nutrition applications. North America leads with 38% market share, followed by Europe at 28% and Asia-Pacific at 24%.GlobeNewswireHuman Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.The global human microbiome market is projected to grow from USD 88.06 million in 2020 to USD 1318.72 million by 2030, a CAGR of 31.08%. North America held the largest regional share at 41.22%, while Asia-Pacific was the fastest-growing region. The therapeutics segment led with a 67.14% share in 2020.PR NewswireMicroBiome Therapeutics Launches Clinically-Tested Dietary Supplement Engineered to Modulate the Gut MicrobiomeMicroBiome Therapeutics announced the launch of BiomeBliss, a prebiotic dietary supplement designed to support gut microbiome health, with results from two clinical studies conducted by Pennington Biomedical Research Center showing benefits including hunger control, regularity, and healthy blood sugar maintenance. The supplement, made from plant-based ingredients including blueberries, agave, and oats, is now available for purchase nationwide through the company's website. The launch is being supported by an e-commerce and social media campaign in partnership with Zehnder Communications, along with a network of registered dietitians and certified diabetic educators.FinSMEsMicroBiome Therapeutics Completes $1M Series B FinancingMicroBiome Therapeutics, a New Orleans-based company, completed a $1M Series B financing with backers including Lagniappe Angels and Zehnder Communications. The funds will support launching its clinically-tested microbiome modulator product in 2018, which has been tested in two clinical trials.PR NewswireMicrobiome Therapeutics Market By Type (Fecal Microbial Transplant [FMT], Drugs) By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease [IBD], Diabetes), By Region And Segment ForecGrand View Research projects the global microbiome therapeutics market will reach USD 433.5 million by 2025, driven by government initiatives like the U.S. Microbiome Initiative and increased funding from entities such as the Bill and Melinda Gates Foundation. Key industry players including Seres Therapeutics, ENTEROME Bioscience, and Johnson & Johnson are forming collaborative agreements to advance drug pipelines for conditions like C. difficile and Crohn's disease.PR NewswireMicrobiome Therapeutics Market, 2015 - 2030ReportBuyer published a market research report titled 'Microbiome Therapeutics Market, 2015-2030' providing analysis on the current landscape and future outlook of microbiome therapeutics, including pipeline products, partnerships, investments, and market forecasts. The report notes that the microbiome therapeutics market is still in its infancy with no approved drugs on the market; Faecal microbial transplant (FMT) remains the only commercially available therapy. The report includes interviews with senior representatives from Assembly Biosciences, Da Volterra, Metabiomics, MicroBiome Therapeutics, and Rebiotix, and highlights growing investor interest in this field.PR NewswireWorld Microbiome Therapeutics Market 2015-2030 - Pipeline in Terms of Phase of Development, Type of Products and Indications - Research and MarketsResearch and Markets published a comprehensive market research report on the microbiome therapeutics market covering the period 2015 to 2030, analyzing over 100 products in clinical and preclinical development. The report found that the market is anticipated to grow at an annual rate of 73%, with approximately USD 0.7 billion in investments recorded during 2014-2015, though no microbiome drugs have been approved yet with only fecal microbiota transplantation (FMT) commercially available. Notable companies in the development pipeline include Seres Therapeutics, Vedanta Biosciences, and Rebiotix, with metabolic and gastrointestinal disorders identified as key therapeutic areas likely to capture significant market share.